This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Malignant salivary gland tumours

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Malignant salivary gland tumors are divided histologically into low-grade and high-grade malignancies:

  • Low-grade malignancies:
    • acinic cell tumors
    • mucoepidermoid carcinoma (grades I or II)
  • High-grade malignancies:
    • mucoepidermoid carcinoma (grade III)
    • adenocarcinoma:
      • poorly differentiated carcinoma
      • anaplastic carcinoma
    • squamous cell carcinoma
    • malignant mixed tumours
    • adenoid cystic carcinoma

The malignant tumours commonly affecting the major salivary glands include:

  • mucoepidermoid carcinoma
  • acinic cell carcinoma,
  • adenoid cystic carcinoma, and less frequently,
  • primary squamous cell carcinomas
  • pleomorphic adenomas, often derived from benign neoplasms

Among minor salivary glands:

  • adenoid cystic carcinoma is the most common
  • adenocarcinoma
  • mucoepidermoid carcinoma

Ref: US National Cancer Instute Salivary Gland Cancer (PDQ®): Treatment

 

Related pages

Create an account to add page annotations

Create a free account

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.